Faron Pharmaceuticals Oy

“"This fundraising is pivotal and comes at an exciting time for Faron. As we will soon see topline data from the Phase II of the BEXMAB clinical trial...The investor interest has been stronger than anticipated which demonstrates that the market shares our strong belief"”

CFO quote uses promotional language ('exciting time', 'market shares our strong belief') to frame a survival fundraise alongside unqualified forward-looking statements about imminent trial data.

Results of Oversubscribed Placing

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.   THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 ("MAR") AND ARTICLE 7 OF MAR AS IT FORMS PART OF UK DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNI…

Faron Pharmaceuticals' LinkedIn page and Proactive Investors referenced a €7.1m share offering (late October 2024) and a larger February 2025 accelerated bookbuild placing that was 1.8x oversubscribed, raising EUR 12m (upsized from EUR 10m target). 6,976,744 shares issued at EUR 1.72. The placing was explicitly designed to address financial covenant requirements. Company acknowledged that without the raise, it could not meet minimum cash covenants agreed with lender IPF.

Faron LinkedIn: linkedin.com/company/faron. Post about new CFO: fi.linkedin.com/posts/faron_faron-pharmaceuticals-moving-into-next-phase-activity-7049404979370958848. The covenant breach risk is well-documented in RNS but LinkedIn posts from the company itself do not highlight this risk prominently.